Advancing the treatment of MDS and AML: An update from ASH 2021

touchCONGRESS for touchONCOLOGY

Listen to Prof. Pierre Fenaux (France) review key data presented at ASH 2021 on emerging treatments for patients with higher-risk MDS and newly diagnosed AML and offer his insights on their potential impact on future clinical practice, alongside those from Dr Esther Oliva (Italy) and Prof. Andrew Wei (Australia).

OVERVIEW

• Data review with Prof. Fenaux (0:00)
• Expert interviews with Prof. Fenaux, Dr Oliva and Prof. Wei, answering the questions below

INTERVIEW QUESTIONS

1. What have we learned about targeting specific mutations in MDS and how will this impact the treatment landscape in the future? (30:30)
2. Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice? (36:13)
3. What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future? (43:15)
4. Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice? (50:06)
5. What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML unfit for intensive chemotherapy? (55:13)

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/mds-aml-ash-2021/